Outcome of Board meeting for Financial Results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma's Board approved unaudited standalone results for Q3 FY26 and the nine months ended Dec 31, 2025. Revenue from operations fell sharply to Rs. 43.26 crore in Q3 FY26, down about 31% from Rs. 62.84 crore in Q3 FY25. For the nine-month period, revenue plunged roughly 62% to Rs. 87.99 crore versus Rs. 233.78 crore a year ago. The company posted a net loss of Rs. 7.32 crore in Q3 (EPS of negative Rs. 1.96), and the nine-month loss widened sharply to Rs. 35.75 crore (negative EPS Rs. 9.55) compared with a Rs. 5.99 crore loss in the same period last year. Two flagged items: a Rs. 3.5 crore insurance claim from a Dec 2023 fire is still pending surveyor's report, and the company has not booked depreciation on its clean room and effluent treatment plants due to non-use. The statutory auditor issued an unqualified limited review report.
Steep revenue contraction and widening losses signal serious business stress, which is likely negative for the stock. Investors should watch for resolution of the fire insurance claim and clarity on whether the depreciation holiday will continue, as these materially affect the true picture of profitability.